Skip to main content

Table 4 SqCC patient characteristics and stratification by neuroendocrine marker

From: Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples

  SqCC overall cohort SqCC neuroendocrine marker positive SqCC neuroendocrine marker negative p value
n % n % n %  
Patients 543 100 80 100 463   
Gender
 Male 451 83 67 84 384 83 0.858
 Female 92 17 13 16 79 17  
Age, median y (range) 65 (38–83) 64 (40–82) 65 (38–83) 0.428
TNM
 pT
  pT1 106 20 16 20 90 19 0.645
  pT2 324 60 48 60 276 60  
  pT3 93 17 15 19 78 17  
  pT4 20 4 1 1 19 4  
 pN
  pN0 255 47 35 44 220 48 0.570
  pN1 179 33 23 29 156 34  
  pN2 98 18 20 25 78 17  
  pN3 1 0 0 0 1 0  
  pNX 10 2 2 3 8 2  
 pM
  pM1 8 1 2 3 6 1  
  pMX 535 99 78 98 457 99  
Stage
 I 185 34 28 35 157 34 0.437
 II 208 38 26 33 182 39  
 III 142 26 24 30 118 25  
 IV 8 1 2 3 6 1  
  1. M metastases, N nodal stage, SqCC squamous cell carcinoma, T tumor size, y year
  2. apN0 versus pN1/pN2/pN3; pNX not included
  3. bstage I versus II versus III/IV